You’ve built something extraordinary. Now make sure it reaches patients. Alkemi helps biotech innovators navigate payers, evidence, and adoption so great science becomes great medicine.
.avif)
.avif)
Biotech companies must navigate complex regulations, diverse healthcare frameworks, and growing payer skepticism. Add in evolving policies like the Inflation Reduction Act, and even breakthrough therapies can struggle to reach patients without the right market access strategy.
That’s where Alkemi comes in. We help biotech teams close the gap between proof of concept and proof of value through:
Evidence planning tailored to payer and HTA expectations
Pricing frameworks grounded in real-world cost and outcomes data
Access plans that chart the fastest path to global adoption
With a data-driven strategy, you can reach patients sooner and position your asset for sustainable commercial success.
Biotech companies must navigate complex regulations, diverse healthcare frameworks, and growing payer skepticism. Add in evolving policies like the Inflation Reduction Act, and even breakthrough therapies can struggle to reach patients without the right market access strategy.
That’s where Alkemi comes in. We help biotech teams close the gap between proof of concept and proof of value through:
Major change in clinical practice or care delivery required
Treatment isn't favorably positioned in clinical guidelines
Low market awareness of unmet need
Treatment is expensive and it's unclear why payers should cover it
Policy is supportive of status quo (which doesn't include your treatment)
With a data-driven strategy, you can reach patients sooner and position your asset for sustainable commercial success.
Biotech companies aren’t pharma and your access plan shouldn’t look like theirs. You’re advancing breakthrough therapies for specialized patient populations with leaner teams, tighter timelines, and higher stakes. Alkemi helps you design market access and HEOR strategies built for this reality, so your innovation reaches the patients who need it most.
We collaborate with biotech leaders from early development through post-launch defense to help you anticipate access challenges before they impact launch, strategize pricing and value communication across markets, and build comprehensive evidence and access plans tailored to each asset’s unique pathway to adoption.
Whether you’re:
Seeking to optimize health technology assessment (HTA)
Preparing for payer negotiations with limited evidence
Convincing investors and partners your product will deliver commercial success
The strongest launches start years before approval. Launch Shield™ is a proactive defense system that helps you design access strategies early by mapping stakeholder needs, shaping trial endpoints, and preparing reimbursement strategies. By the time you reach launch, every piece is in place for coverage, adoption, and global expansion.
Starting at
$150k
When your product is already under pressure, you need a plan fast. Alkemi’s Access Threat Response System™ helps you realign teams, rebuild confidence with payers, and deploy a launch-ready strategy in 90 days or less.
Starting at
$100k
We translate clinical trial data and real world evidence into health economics and outcomes research that speaks to payers and regulatory bodies. This evidence package strengthens global value dossiers to achieve positive HTA and pricing decisions.
Our team builds clear, actionable market access and HEOR plans — not just slide decks. These include evidence generation, economic modeling, guidelines positioning, stakeholder engagement, launch sequence and pricing plans designed to achieve market access and secure broad adoption.
From the early stages of drug development through commercialization, Alkemi equips your HEOR and market access teams with the tools and frameworks to address access barriers, anticipate market dynamics, and adapt pricing strategies in real time.
Biotech companies may need to build commercial capabilities and novel funding pathways, in addition to demonstrating patient outcomes and making a clear value case to payers. We'll help you reach patients while helping your organization thrive.
Biotech companies come to Alkemi when they’re ready to scale from scientific validation to market validation.
Our team has supported more than 50 global launches, including some of the toughest rare disease and specialty therapy introductions. We’ve helped innovators secure payer alignment, streamline HTA readiness, achieve guideline inclusion, and accelerate market adoption in record time.
Our consultants build 90-day access strategies that align evidence, pricing, and stakeholder engagement—so teams move fast, stay coordinated, and gain early traction with decision-makers.
When you need a partner who understands the biotech mindset and the realities of global market access, you call Alkemi.
“Their strategic insights and support were essential – they have a knack for communicating differentiated value.”
![image of successful businesses [headshot]](https://cdn.prod.website-files.com/68c86636bce64aae0bd583b2/68c86c59ad68004ea9ddd6b4_c1cd2a51-1f06-45cb-9a13-4199a77f0015.avif)
“They helped us identify our evidence gaps and develop a solid communication tool aligned with stakeholder needs. And they’re fun to work with!”
![[headshot]](https://cdn.prod.website-files.com/68c86636bce64aae0bd583b2/68c86c59dcf34a6442165770_122204b6-f407-479f-9bb7-84c323ad8f65.avif)
“Excellent work! Alkemi was prepared with the details, holistic with the assessments, and strategic in the approach. I would not hesitate to use them again.”
![[headshot] image of customer (for a home inspector)](https://cdn.prod.website-files.com/68c86636bce64aae0bd583b2/68c86c5aee875a9e30534dab_da918c69-68ea-42eb-8ad0-fd4f176193a5.avif)
"When I presented the project output to our leadership, they said: 'You took a really scary situation and broke it down in terms we understand. It sounds like the team has a clear plan going forward'.
“Great feedback continues on the ‘buzz’ … this is from president of intl…thank you to your entire team! Keep up the great work!!”
“Their strategic insights and support were essential – they have a knack for communicating differentiated value.”
“In a record 3.5 days, guidelines have been updated to include [treatment]. Woohoo!!”
Biotech moves fast. Regulations change. Data evolves. Markets shift.
That’s why Alkemi’s strategies are built for agility and resilience. We stay engaged as your asset advances, refining evidence, messaging, and access plans as new payer signals or policy shifts emerge.
We stand behind our work. Every project comes with our satisfaction guarantee. If something isn’t right, we’ll make it right. Because in biotech, agility is just as important as accuracy.
Every Alkemi engagement delivers a practical roadmap to market access, purpose-built for biotech teams bringing breakthroughs to market.
We map the entire access landscape, from payers and HTA bodies to competitive pipelines and policy shifts. This lets you see exactly where your product is vulnerable and where opportunities exist to strengthen your value story.
We uncover the precise evidence and messaging payers, HTA, guidelines and health systems need to greenlight your treatment. From those insights, we shape evidence and messaging that resonates with decision-makers to help you overcome hurdles to access.
In biotech, internal silos cost time and market share. Our frameworks align global, regional, and local teams around one clear market access strategy to keep your launch on track.
We build payer- and HTA-ready playbooks with validated arguments, counterstrategies, and stakeholder-tested messaging. You’ll know exactly how to navigate pricing discussions, defend value positioning, and secure alignment across decision-makers.
Coverage is only the start. We provide rollout briefs and pull-through strategies that make it easier for prescribers, health systems, and payers to say yes, so innovative treatments reach appropriate patients without delay.
Schedule a strategy call with Alkemi and gain a partner who understands both the science you’re advancing and the access systems you must navigate. Together, we’ll build the strategy that secures payer alignment, accelerates adoption, and gets your treatment to patients faster.
“Access strategies executed in 90 days instead of 6-12 months, enabling us to act within the critical 30-day decision window, when access positions were still in flux and competitors were unprepared.”
“I wanted to reach out and tell you that the publication is getting GREAT reception from senior BU leadership across the company. Thank you again for your and Alkemi’s support on this project!”
“Stakeholder-validated access arguments built in 42 days, helping us retain Tier 2 formulary status and neutralize a competitor’s evidence positioning before revenue was impacted.”
“Payer value models and communication tools delivered in 45 days, giving our team immediate readiness for coverage discussions, cutting months from pricing and reimbursement timelines.”
"Really appreciate your support - as you know I rang you in a bit of a panic a few weeks ago, yet the session came across as though you’d been working on it for months. Thank you so much - this is an important event for our team, companies and clients - and you really helped make it a success. I heard 3 groups leave with ambitions to up their game - and they’re the 3 that need to do it the most - so the message landed as well."
“Patient access achieved 6 days post-approval, driving a 140% revenue increase and 90% share-price growth within 12 months through a precision-aligned market access plan.”
“Coverage positions worth $100M+ preserved after policy risks were contained and access arguments re-framed within 45 days of the initial threat.”
"When I presented the project output to our leadership, they said: 'You took a really scary situation and broke it down in terms we understand. It sounds like the team has a clear plan going forward'.
“Launch readiness across 7 key markets accelerated by 6 months, improving payer perception, price confidence, and HTA alignment for sustained commercial success.”
“Cross-functional alignment reached in 21 days, uniting medical, HEOR, and commercial stakeholders around payer-critical priorities and evidence generation plans.”
“Research engagement delivered 5X more patients and 6X more clinicians than prior studies, compressing evidence-collection timelines by over 12 months.”
"Thanks to the whole team involved in staging this Advisory Council. I was fortunate to be able to attend and here the insights from the council members firsthand. The report provides an excellent summary."
“Guideline and compendia updates secured within 7 days of approval, converting scientific validation into immediate payer endorsement and market adoption.”